GlassScriptPhysician profile
Shubham Pant
NPI 1831300318
$191,462.06
in general payments reported to CMS, 2019-2025
29 companies · $64K in 2025
The $64K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $4,018 · 2021: $16K · 2022: $4,911 · 2023: $42K · 2024: $61K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $21K · Honoraria: $20K · Food and Beverage: $2,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,499.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,135.91 |
| Travel and Lodging | $20,667.08 |
| Honoraria | $19,655.00 |
| Food and Beverage | $2,897.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $57,653.06 | 2020-2025 | Onivyde, Tazverik, Somatuline Depot |
| Jazz Pharmaceuticals INC. | $37,456.46 | 2023-2025 | Zanidatamab |
| E.R. Squibb & Sons, L.L.C. | $25,760.81 | 2025 | |
| Boehringer Ingelheim International Gmbh | $23,523.40 | 2021-2024 | |
| Uswm, LLC | $14,000.00 | 2023 | |
| Merck Sharp & Dohme LLC | $8,384.22 | 2024 | Keytruda |
| Janssen Research & Development, LLC | $6,750.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $4,716.00 | 2021 | |
| Pfizer INC. | $3,737.50 | 2025 | |
| Emd Serono Research & Development Institute, INC. | $3,195.00 | 2025 | |
| Daiichi Sankyo INC. | $2,460.00 | 2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,220.00 | 2024 | |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $1,213.41 | 2020 | |
| Trisalus Life Sciences, INC. | $201.84 | 2022-2023 | Trinav Infusion System |
| Astrazeneca Pharmaceuticals LP | $128.78 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $30.90 | 2023 | Krazati |
| Octapharma USA, INC. | $30.68 | 2019 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shubham Pant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.